Management of BPH with Concurrent Erectile Dysfunction
Initial Treatment Strategy
- The American Urological Association recommends initiating treatment with a PDE5 inhibitor, specifically tadalafil 5 mg once daily, as first-line monotherapy for patients with BPH and erectile dysfunction, addressing both conditions simultaneously 1, 2, 3
- The 2021 AUA guideline algorithm states that if a patient also has ED, they can start with PDE5s as initial therapy, which is recommended for patients presenting with both BPH/LUTS and ED 1, 2, 3
When to Add or Switch Therapy
- If prostate volume exceeds 30 grams, consider adding a 5-ARI (finasteride or dutasteride) to the PDE5 inhibitor regimen, which addresses both the static component and improves symptoms while maintaining erectile function 1, 2, 3
Follow-Up and Reassessment
- Reassess patients at 4-12 weeks after initiating PDE5 inhibitor therapy, using the International Prostate Symptom Score (IPSS) to objectively measure response, and consider post-void residual (PVR) and uroflowmetry for additional objective assessment 1, 2, 3
- Patients without symptom improvement or experiencing intolerable side effects should undergo further evaluation and consideration of changing medical management or surgical intervention, which may indicate the need for combination therapy with 5-ARI or consideration of procedural options 1, 2, 3